Opus Genetics, a Penn startup based on technology developed by Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology at Penn Medicine, announced positive data in a clinical trial for the treatment of Leber Congenital Amaurosis Type 5 (LCA5), an inherited retinal disease. These findings suggest OPGx-LCA5, Opus Genetics’ investigational gene augmentation therapy, could improve vision for patients previously considered untreatable, a major step toward reversing inherited blindness in LCA5 patients. Read more here.